About
Congratulations | AIM Vaccine mRNA RSV Vaccine Approved for Clinical Trials in the U.S.
Release Time：
2025-02-28 13:34
Source：
On February 26, 2025, AIM Vaccine announced that its mRNA Respiratory Syncytial Virus (RSV) vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). This marks the company’s first FDA clinical approval in the U.S.
In preclinical animal studies, third-party testing results showed that the vaccine outperformed currently available international mRNA RSV vaccines in several key indicators, including specific IgG antibody titers, neutralizing antibody titers against the live virus, and specific T-cell immunity.
RSV is a common respiratory pathogen with high infectivity, widespread globally, and a major cause of severe respiratory illness, particularly in infants under one year old and the elderly. It is also a significant factor in respiratory-related deaths in older adults. Additionally, those previously infected with RSV remain at risk of reinfection. Currently, there are no FDA-approved antiviral drugs specifically for RSV infection, making vaccination an effective way to prevent severe RSV cases.
As a close partner of AIM Vaccine, Levostar Biotech has played a crucial role in the development and submission of this mRNA RSV vaccine, particularly in the characterization and testing of the mRNA formulation. We would like to extend our warm congratulations to AIM Vaccine for the successful FDA clinical trial approval of their RSV mRNA vaccine.
About AIM Vaccine
AIM Vaccine is one of China’s earliest companies to develop mRNA vaccine products and was among the first domestic vaccine enterprises to secure independent patents for mRNA technology. The company has a well-established mRNA vaccine R&D system and a comprehensive quality management system, alongside GMP-compliant commercial production facilities. Notably, their mRNA technology platform has undergone clinical trials involving over 10,000 human cases, successfully validating the entire lifecycle process from development to production. This enables rapid industrialization of mRNA vaccines after clinical completion, accelerating their commercialization process.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898